Researchers investigate a novel treatment for Childhood Alzheimer’s
Category: #health  By Saipriya Iyer  Date: 2020-06-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Researchers investigate a novel treatment for Childhood Alzheimer’s

Researchers at the Lundquist Institute have reportedly collaborated with the Cure Sanfilippo Foundation on a new clinical trial to investigate if repurposing an anti-inflammatory drug could provide relief to children that suffer from Sanfilippo syndrome, also referred as Childhood Alzheimer’s.

With majority of clinical trials currently focused on finding a vaccine for COVID-19, the team at The Lundquist Institute continues its efforts towards developing a treatment for Sanfilippo syndrome as safely and quickly as possible.

For the record, Sanfilippo syndrome, also known as MPS III (mucopolysaccharidosis type III), is a rare genetic disorder that has distressing effect on patient’s nervous system. People affected with this disease lack an enzyme that helps break down large sugar molecules in the body.

According to credible sources, the clinical trial was designed by Drs. Agnes Chen and Lynda Polgreen from The Lundquist Institute in partnership with Dr. Cara O’Neill, Chief Science Officer at Cure Sanfilippo Foundation and Dr. Julie Eisengart, Director, Neurodevelopmental Program in Rare Disease at UNM Medical School.

Reports claim that Dr. Cara O’Neill effectively recognized the potential of new research around the role of inflammation in this disease and how current FDA-approved treatments could ameliorate symptoms in patients. She identified pharmaceutical and clinical partners to utilize this concept in a clinical trial for children suffering from Sanfilippo Syndrome, leading her to The Lundquist Institute.

Elaborating on anticipated developments, the clinical trial is estimated to begin in May whilst involving 20 children with Sanfilippo syndrome. The candidates will be given anakinra, which blocks the activity of a protein called interleukin-1 (IL-1) that leads to joint damage, thereby lowering inflammation.

Repurposing a preexisting drug to treat patients with Sanfilippo syndrome could endow a cost-efficient as well as timely way to enhance the quality of living of children suffering from this fatal disease.

Source Credit: https://www.businesswire.com/news/home/20200624005203/en/Unique-Clinical-Trial-Investigates-New-Treatment-Approach



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Tetra Pak announces target to reach net-zero GHG emissions by 2030
Tetra Pak announces target to reach net-zero GHG emissions by 2030
By Saipriya Iyer

Tetra Pak, a food processing and packaging solutions provider, has recently announced its target to reach net-zero GHG (greenhouse gas) emissions in its operations by 2030.

The targ...

DTE Energy pledges to reach net-zero emissions of GHG by 2050
DTE Energy pledges to reach net-zero emissions of GHG by 2050
By Saipriya Iyer

DTE Energy has reportedly pledged to reach the net-zero GHG (greenhouse gas) emissions by 2050. This can be ensured through various actions involving customers, suppliers, and its infrastructure, that align with the lo...

Amazon unveils $2 billion climate fund to help decarbonize economies
Amazon unveils $2 billion climate fund to help decarbonize economies
By Saipriya Iyer

Amazon, the renowned technology and online retail giant, has reportedly announced a new initiative that would help efforts to develop sustainable technologies, products, and services that would allow Amazon and several...